AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann–Pick type C1 disease
Open Access
- 5 June 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 27 (17) , 3079-3098
Abstract
Niemann–Pick type C disease (NP-C) is a fatal neurodegenerative lysosomal storage disorder. It is caused in 95% of cases by a mutation in the NPC1 gene that encodes NPC1, an integral transmembrane protein localized to the limiting membrane of the lysosome. There is no cure for NP-C but there is a disease-modifying drug (miglustat) that slows disease progression but with associated side effects. Here, we demonstrate in a well-characterized mouse model of NP-C that a single administration of AAV-mediated gene therapy to the brain can significantly extend lifespan, improve quality of life, prevent or ameliorate neurodegeneration, reduce biochemical pathology and normalize or improve various indices of motor function. Over-expression of human NPC1 does not cause adverse effects in the brain and correctly localizes to late endosomal/lysosomal compartments. Furthermore, we directly compare gene therapy to licensed miglustat. Even at a low dose, gene therapy has all the benefits of miglustat but without adverse effects. On the basis of these findings and on-going ascendency of the field, we propose intracerebroventricular gene therapy as a potential therapeutic option for clinical use in NP-C.Keywords
Funding Information
- Medical Research Council (MR/N026101/1)
- Asociación Niemann-Pick de Fuenlabrada Spain
- Seventh Framework Programme (H-1501)
This publication has 46 references indexed in Scilit:
- Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profilingJournal of Lipid Research, 2013
- Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyJournal of Clinical Investigation, 2013
- Early glial activation, synaptic changes and axonal pathology in the thalamocortical system of Niemann–Pick type C1 miceNeurobiology of Disease, 2012
- Systemic Errors in Quantitative Polymerase Chain Reaction Titration of Self-Complementary Adeno-Associated Viral Vectors and Improved Alternative MethodsHuman Gene Therapy Methods, 2012
- Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustatOrphanet Journal of Rare Diseases, 2012
- In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expressionGene Therapy, 2011
- Unesterified Cholesterol Accumulation in Late Endosomes/Lysosomes Causes Neurodegeneration and Is Prevented by Driving Cholesterol Export from This CompartmentJournal of Neuroscience, 2011
- Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acidJournal of Lipid Research, 2010
- Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease ProgressionPLOS ONE, 2009
- Murine models of acute neuronopathic Gaucher diseaseProceedings of the National Academy of Sciences, 2007